Annexon reports Q1 net loss $38.7M; pipeline milestones expected through 2024

Annexon, Inc.

2023-Q3 EPS reported -$0.52

Net loss $38.7M ($0.52/sh) vs $35.4M ($0.92/sh) in Q1 2022; R&D spend rose to $32.3M.
Cash and investments $228.2M; runway into 2025 for ongoing trials.
Phase 2 ARCHER trial of ANX007 in geographic atrophy data expected mid-2023.
Phase 3 GBS trial enrollment completion 2H'23; topline results 1H'24.
Initial Phase 1b data for ANX009 in lupus nephritis due 1H'23; ANX1502 oral data 2H'23.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Annexon, Inc. reported the first quarter ended March 31, 2023 results: net income Net loss was $38.7 million or $0.52 per share.

Period: the first quarter ended March 31, 2023
Net income: Net loss was $38.7 million or $0.52 per share
Result: reported results

Exact text from the filing

On May 8, 2023, Annexon, Inc. (the “Company”) announced certain financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Annexon, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-018810

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.